WebHoward Richman, the former chief of regulatory affairs for Biopure, agreed to pay a $150,000 fine to settle federal charges that he had helped mislead investors in the … WebBiopure BiopureCorporation was a biopharmaceutical company that specialized in oxygen therapeutics for both human and veterinary use. The company developed, manufactured, and marketed oxygen therapeutics, designed to transport oxygen to the body's tissues.
Ex-Biopure Head Settles SEC Blood Substitute Case - Law360
WebLaw360 (October 6, 2009, 6:23 PM EDT) -- A federal judge has sentenced the former head of regulatory affairs at Biopure Corp. to the maximum three years in prison and a $50,000 fine for faking... WebView the profiles of professionals named "Howard Richman" on LinkedIn. There are 20+ professionals named "Howard Richman", who use LinkedIn to exchange information, … focal points of a debate crossword clue
Howard Richman, former VP of BioPure, pleads guilty to
WebThe action, filed in federal district court in Massachusetts, charges Biopure, its former CEO Thomas Moore, 54, of Boston, former Senior Vice President of Regulatory Affairs and … WebHoward P. Richman, Criminal Action. No. 08-10282-MLW (D. Mass.) The Commission announced today that on September 24, 2008, Howard Richman, the former head of … With such a promising technology, Biopure was faced with many issues that have led to the company’s current condition. By 1999, the US FDA and European Commission had approved Oxyglobin for the treatment for anemic dogs. By April 2001, South Africa’s Medicine Control Council approved Hemopure for treatment of surgical patients who are acutely anemic, to help generate revenue for the company. However, Biopure’s global commercialization strategy of ma… focal point risk